English
简体中文
Total: £ 56.28
Published Date: 2025-09-11 | Pages: 71 | Tables: 78 | Pharma & Healthcare
The global market for Long-Acting HIV-1 Inhibitors was valued at US$ 347 million in the year 2024 and is projected to reach a revised size of US$ 496 million by 2031, growing at a CAGR of 4.5% during the forecast period.
Long-Acting HIV-1 Inhibitors represent a class of antiretroviral formulations that utilize innovative pharmaceutical technologies (e.g., nanocrystals, liposomal encapsulation, or prodrug design) to extend drug duration in the body, with the primary goal of transitioning from daily oral dosing to dosing intervals of weeks or months. These medications maintain stable drug concentrations to sustainably suppress viral replication, significantly improving patient adherence and reducing side effects, particularly suitable for long-term HIV management and pre-exposure prophylaxis (PrEP). Current formulations include intramuscular injections, subcutaneous implants, and extended-release oral dosage forms, with technological barriers primarily lying in complex drug delivery system design and controlled release kinetics.
From a supply chain perspective, the upstream sector involves the supply of high-purity active pharmaceutical ingredients (APIs), specialty excipients (e.g., biodegradable polymers, stabilizers), and advanced packaging materials (e.g., pre-filled syringes). The midstream encompasses complex formulation development (including pharmacokinetic studies and stability testing), sterile manufacturing under GMP standards, and rigorous quality control systems. Downstream distribution occurs through specialized pharmaceutical logistics channels, disease control centers, and designated pharmacies to reach end patients, requiring配套 professional healthcare training and usage guidance. Key supply chain challenges include ensuring stable supply of specialty excipients, meeting cold chain logistics requirements, and navigating complex multinational regulatory compliance, necessitating interdisciplinary technology integration and global collaboration capabilities.
North American market for Long-Acting HIV-1 Inhibitors is estimated to increase from $ million in 2024 to reach $ million by 2031, at a CAGR of % during the forecast period of 2025 through 2031.
Asia-Pacific market for Long-Acting HIV-1 Inhibitors is estimated to increase from $ million in 2024 to reach $ million by 2031, at a CAGR of % during the forecast period of 2025 through 2031.
The global market for Long-Acting HIV-1 Inhibitors in Hospital is estimated to increase from $ million in 2024 to $ million by 2031, at a CAGR of % during the forecast period of 2025 through 2031.
The major global companies of Long-Acting HIV-1 Inhibitors include GSK, Frontier Biotechnologies, Gilead Sciences, ViiV Healthcare, Johnson & Johnson, MSD, etc. In 2024, the world's top three vendors accounted for approximately % of the revenue.
This report aims to provide a comprehensive presentation of the global market for Long-Acting HIV-1 Inhibitors, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Long-Acting HIV-1 Inhibitors.
The Long-Acting HIV-1 Inhibitors market size, estimations, and forecasts are provided in terms of and revenue ($ millions), considering 2024 as the base year, with history and forecast data for the period from 2020 to 2031. This report segments the global Long-Acting HIV-1 Inhibitors market comprehensively. Regional market sizes, concerning products by Type, by Application, and by players, are also provided.
For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.
The report will help the Long-Acting HIV-1 Inhibitors companies, new entrants, and industry chain related companies in this market with information on the revenues for the overall market and the sub-segments across the different segments, by company, by Type, by Application, and by regions.
Market Segmentation
By Company
GSK
Frontier Biotechnologies
Gilead Sciences
ViiV Healthcare
Johnson & Johnson
MSD
Segment by Type
Long-Acting Injection
Long-Acting Oral
Segment by Application
Hospital
Clinic
Others
By Region
North America
U.S.
Canada
Asia-Pacific
China
Japan
South Korea
Southeast Asia
India
Australia & New Zealand
Europe
Germany
France
U.K.
Italy
Ireland
Russia
Rest of Europe
Latin America
Mexico
Brazil
Argentina
Middle East & Africa
Israel
United Arab Emirates (UAE)
Saudi Arabia
Chapter Outline
Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by Type, by Application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Introduces executive summary of global market size, regional market size, this section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.
Chapter 3: Detailed analysis of Long-Acting HIV-1 Inhibitors company competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6, 7, 8, 9, 10: North America, Europe, Asia Pacific, Latin America, Middle East and Africa segment by country. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.
Chapter 11: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 12: The main points and conclusions of the report.
Research Methodology
The research methodology employed has been subjected by numerous procedures in order to guarantee the quality and accuracy of the data contained within the reports. The analysts are employed full-time and received more than six months training to satisfy the standard of our company. Our methodology can be divided into five stages:
★Stage 1 SECONDARY RESEARCH
The research team first collaborates with magazines, trade associations and administrative departments in the research field. The information provided by our internal documentation service is helpful for our further research. Our team has a wealth of experience and knowledge, and can effectively extract accurate information from existing resources.
★Stage 2 PRIMARY RESEARCH:INTERVIEWS WITH TRADE SOURCES
After the first stage, the research team conducts a large number of face-to-face or telephone interviews with representative companies working in the research field. Analysts are trying to have an opportunity to talk to leading companies and small companies in the field. Upstream suppliers, manufacturers, distributors, importers, installers, wholesalers and consumers were included in the interview. The data collected during the interview were then carefully examined and compared with the secondary study.
★Stage 3 ANALYSIS OF THE GATHERED DATA
The analysis team examines and synthesizes the data collected in the first two stages. In order to validate the data, a second round of interviews can be conducted.
★Stage 4 QUANTITATIVE DATA
The quantitative data such as market estimates, production and capacity of manufacturer, market forecasts and investment feasibility is provided by our company. The data is based on the estimates obtained during stage 3.
★Stage 5 QUALITY CONTROL
Before publishing, each report undergoes a rigorous review and editing process, which is done by the experience management team to ensure the reliability of the published data. Every analyst on the research team receives support and continuous training as part of our internal quality process.
1 Report Overview
1.1 Study Scope
1.2 Market Analysis by Type
1.2.1 Global Long-Acting HIV-1 Inhibitors Market Size Growth Rate by Type: 2020 VS 2024 VS 2031
1.2.2 Long-Acting Injection
1.2.3 Long-Acting Oral
1.3 Market by Application
1.3.1 Global Long-Acting HIV-1 Inhibitors Market Growth by Application: 2020 VS 2024 VS 2031
1.3.2 Hospital
1.3.3 Clinic
1.3.4 Others
1.4 Assumptions and Limitations
1.5 Study Objectives
1.6 Years Considered
2 Global Growth Trends
2.1 Global Long-Acting HIV-1 Inhibitors Market Perspective (2020-2031)
2.2 Global Long-Acting HIV-1 Inhibitors Growth Trends by Region
2.2.1 Global Long-Acting HIV-1 Inhibitors Market Size by Region: 2020 VS 2024 VS 2031
2.2.2 Long-Acting HIV-1 Inhibitors Historic Market Size by Region (2020-2025)
2.2.3 Long-Acting HIV-1 Inhibitors Forecasted Market Size by Region (2026-2031)
2.3 Long-Acting HIV-1 Inhibitors Market Dynamics
2.3.1 Long-Acting HIV-1 Inhibitors Industry Trends
2.3.2 Long-Acting HIV-1 Inhibitors Market Drivers
2.3.3 Long-Acting HIV-1 Inhibitors Market Challenges
2.3.4 Long-Acting HIV-1 Inhibitors Market Restraints
3 Competition Landscape by Key Players
3.1 Global Top Long-Acting HIV-1 Inhibitors Players by Revenue
3.1.1 Global Top Long-Acting HIV-1 Inhibitors Players by Revenue (2020-2025)
3.1.2 Global Long-Acting HIV-1 Inhibitors Revenue Market Share by Players (2020-2025)
3.2 Global Top Long-Acting HIV-1 Inhibitors Players by Company Type and Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
3.3 Global Key Players Ranking by Long-Acting HIV-1 Inhibitors Revenue
3.4 Global Long-Acting HIV-1 Inhibitors Market Concentration Ratio
3.4.1 Global Long-Acting HIV-1 Inhibitors Market Concentration Ratio (CR5 and HHI)
3.4.2 Global Top 10 and Top 5 Companies by Long-Acting HIV-1 Inhibitors Revenue in 2024
3.5 Global Key Players of Long-Acting HIV-1 Inhibitors Head office and Area Served
3.6 Global Key Players of Long-Acting HIV-1 Inhibitors, Product and Application
3.7 Global Key Players of Long-Acting HIV-1 Inhibitors, Date of Enter into This Industry
3.8 Mergers & Acquisitions, Expansion Plans
4 Long-Acting HIV-1 Inhibitors Breakdown Data by Type
4.1 Global Long-Acting HIV-1 Inhibitors Historic Market Size by Type (2020-2025)
4.2 Global Long-Acting HIV-1 Inhibitors Forecasted Market Size by Type (2026-2031)
5 Long-Acting HIV-1 Inhibitors Breakdown Data by Application
5.1 Global Long-Acting HIV-1 Inhibitors Historic Market Size by Application (2020-2025)
5.2 Global Long-Acting HIV-1 Inhibitors Forecasted Market Size by Application (2026-2031)
6 North America
6.1 North America Long-Acting HIV-1 Inhibitors Market Size (2020-2031)
6.2 North America Long-Acting HIV-1 Inhibitors Market Growth Rate by Country: 2020 VS 2024 VS 2031
6.3 North America Long-Acting HIV-1 Inhibitors Market Size by Country (2020-2025)
6.4 North America Long-Acting HIV-1 Inhibitors Market Size by Country (2026-2031)
6.5 United States
6.6 Canada
7 Europe
7.1 Europe Long-Acting HIV-1 Inhibitors Market Size (2020-2031)
7.2 Europe Long-Acting HIV-1 Inhibitors Market Growth Rate by Country: 2020 VS 2024 VS 2031
7.3 Europe Long-Acting HIV-1 Inhibitors Market Size by Country (2020-2025)
7.4 Europe Long-Acting HIV-1 Inhibitors Market Size by Country (2026-2031)
7.5 Germany
7.6 France
7.7 U.K.
7.8 Italy
7.9 Russia
7.10 Ireland
8 Asia-Pacific
8.1 Asia-Pacific Long-Acting HIV-1 Inhibitors Market Size (2020-2031)
8.2 Asia-Pacific Long-Acting HIV-1 Inhibitors Market Growth Rate by Region: 2020 VS 2024 VS 2031
8.3 Asia-Pacific Long-Acting HIV-1 Inhibitors Market Size by Region (2020-2025)
8.4 Asia-Pacific Long-Acting HIV-1 Inhibitors Market Size by Region (2026-2031)
8.5 China
8.6 Japan
8.7 South Korea
8.8 Southeast Asia
8.9 India
8.10 Australia & New Zealand
9 Latin America
9.1 Latin America Long-Acting HIV-1 Inhibitors Market Size (2020-2031)
9.2 Latin America Long-Acting HIV-1 Inhibitors Market Growth Rate by Country: 2020 VS 2024 VS 2031
9.3 Latin America Long-Acting HIV-1 Inhibitors Market Size by Country (2020-2025)
9.4 Latin America Long-Acting HIV-1 Inhibitors Market Size by Country (2026-2031)
9.5 Mexico
9.6 Brazil
10 Middle East & Africa
10.1 Middle East & Africa Long-Acting HIV-1 Inhibitors Market Size (2020-2031)
10.2 Middle East & Africa Long-Acting HIV-1 Inhibitors Market Growth Rate by Country: 2020 VS 2024 VS 2031
10.3 Middle East & Africa Long-Acting HIV-1 Inhibitors Market Size by Country (2020-2025)
10.4 Middle East & Africa Long-Acting HIV-1 Inhibitors Market Size by Country (2026-2031)
10.5 Israel
10.6 Saudi Arabia
10.7 UAE
11 Key Players Profiles
11.1 GSK
11.1.1 GSK Company Details
11.1.2 GSK Business Overview
11.1.3 GSK Long-Acting HIV-1 Inhibitors Introduction
11.1.4 GSK Revenue in Long-Acting HIV-1 Inhibitors Business (2020-2025)
11.1.5 GSK Recent Development
11.2 Frontier Biotechnologies
11.2.1 Frontier Biotechnologies Company Details
11.2.2 Frontier Biotechnologies Business Overview
11.2.3 Frontier Biotechnologies Long-Acting HIV-1 Inhibitors Introduction
11.2.4 Frontier Biotechnologies Revenue in Long-Acting HIV-1 Inhibitors Business (2020-2025)
11.2.5 Frontier Biotechnologies Recent Development
11.3 Gilead Sciences
11.3.1 Gilead Sciences Company Details
11.3.2 Gilead Sciences Business Overview
11.3.3 Gilead Sciences Long-Acting HIV-1 Inhibitors Introduction
11.3.4 Gilead Sciences Revenue in Long-Acting HIV-1 Inhibitors Business (2020-2025)
11.3.5 Gilead Sciences Recent Development
11.4 ViiV Healthcare
11.4.1 ViiV Healthcare Company Details
11.4.2 ViiV Healthcare Business Overview
11.4.3 ViiV Healthcare Long-Acting HIV-1 Inhibitors Introduction
11.4.4 ViiV Healthcare Revenue in Long-Acting HIV-1 Inhibitors Business (2020-2025)
11.4.5 ViiV Healthcare Recent Development
11.5 Johnson & Johnson
11.5.1 Johnson & Johnson Company Details
11.5.2 Johnson & Johnson Business Overview
11.5.3 Johnson & Johnson Long-Acting HIV-1 Inhibitors Introduction
11.5.4 Johnson & Johnson Revenue in Long-Acting HIV-1 Inhibitors Business (2020-2025)
11.5.5 Johnson & Johnson Recent Development
11.6 MSD
11.6.1 MSD Company Details
11.6.2 MSD Business Overview
11.6.3 MSD Long-Acting HIV-1 Inhibitors Introduction
11.6.4 MSD Revenue in Long-Acting HIV-1 Inhibitors Business (2020-2025)
11.6.5 MSD Recent Development
12 Analyst's Viewpoints/Conclusions
13 Appendix
13.1 Research Methodology
13.1.1 Methodology/Research Approach
13.1.1.1 Research Programs/Design
13.1.1.2 Market Size Estimation
13.1.1.3 Market Breakdown and Data Triangulation
13.1.2 Data Source
13.1.2.1 Secondary Sources
13.1.2.2 Primary Sources
13.2 Author Details
13.3 Disclaimer
List of Tables
Table 1. Global Long-Acting HIV-1 Inhibitors Market Size Growth Rate by Type (US$ Million): 2020 VS 2024 VS 2031
Table 2. Key Players of Long-Acting Injection
Table 3. Key Players of Long-Acting Oral
Table 4. Global Long-Acting HIV-1 Inhibitors Market Size Growth by Application (US$ Million): 2020 VS 2024 VS 2031
Table 5. Global Long-Acting HIV-1 Inhibitors Market Size by Region (US$ Million): 2020 VS 2024 VS 2031
Table 6. Global Long-Acting HIV-1 Inhibitors Market Size by Region (2020-2025) & (US$ Million)
Table 7. Global Long-Acting HIV-1 Inhibitors Market Share by Region (2020-2025)
Table 8. Global Long-Acting HIV-1 Inhibitors Forecasted Market Size by Region (2026-2031) & (US$ Million)
Table 9. Global Long-Acting HIV-1 Inhibitors Market Share by Region (2026-2031)
Table 10. Long-Acting HIV-1 Inhibitors Market Trends
Table 11. Long-Acting HIV-1 Inhibitors Market Drivers
Table 12. Long-Acting HIV-1 Inhibitors Market Challenges
Table 13. Long-Acting HIV-1 Inhibitors Market Restraints
Table 14. Global Long-Acting HIV-1 Inhibitors Revenue by Players (2020-2025) & (US$ Million)
Table 15. Global Long-Acting HIV-1 Inhibitors Market Share by Players (2020-2025)
Table 16. Global Top Long-Acting HIV-1 Inhibitors Players by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Long-Acting HIV-1 Inhibitors as of 2024)
Table 17. Ranking of Global Top Long-Acting HIV-1 Inhibitors Companies by Revenue (US$ Million) in 2024
Table 18. Global 5 Largest Players Market Share by Long-Acting HIV-1 Inhibitors Revenue (CR5 and HHI) & (2020-2025)
Table 19. Global Key Players of Long-Acting HIV-1 Inhibitors, Headquarters and Area Served
Table 20. Global Key Players of Long-Acting HIV-1 Inhibitors, Product and Application
Table 21. Global Key Players of Long-Acting HIV-1 Inhibitors, Date of Enter into This Industry
Table 22. Mergers & Acquisitions, Expansion Plans
Table 23. Global Long-Acting HIV-1 Inhibitors Market Size by Type (2020-2025) & (US$ Million)
Table 24. Global Long-Acting HIV-1 Inhibitors Revenue Market Share by Type (2020-2025)
Table 25. Global Long-Acting HIV-1 Inhibitors Forecasted Market Size by Type (2026-2031) & (US$ Million)
Table 26. Global Long-Acting HIV-1 Inhibitors Revenue Market Share by Type (2026-2031)
Table 27. Global Long-Acting HIV-1 Inhibitors Market Size by Application (2020-2025) & (US$ Million)
Table 28. Global Long-Acting HIV-1 Inhibitors Revenue Market Share by Application (2020-2025)
Table 29. Global Long-Acting HIV-1 Inhibitors Forecasted Market Size by Application (2026-2031) & (US$ Million)
Table 30. Global Long-Acting HIV-1 Inhibitors Revenue Market Share by Application (2026-2031)
Table 31. North America Long-Acting HIV-1 Inhibitors Market Size Growth Rate by Country (US$ Million): 2020 VS 2024 VS 2031
Table 32. North America Long-Acting HIV-1 Inhibitors Market Size by Country (2020-2025) & (US$ Million)
Table 33. North America Long-Acting HIV-1 Inhibitors Market Size by Country (2026-2031) & (US$ Million)
Table 34. Europe Long-Acting HIV-1 Inhibitors Market Size Growth Rate by Country (US$ Million): 2020 VS 2024 VS 2031
Table 35. Europe Long-Acting HIV-1 Inhibitors Market Size by Country (2020-2025) & (US$ Million)
Table 36. Europe Long-Acting HIV-1 Inhibitors Market Size by Country (2026-2031) & (US$ Million)
Table 37. Asia-Pacific Long-Acting HIV-1 Inhibitors Market Size Growth Rate by Region (US$ Million): 2020 VS 2024 VS 2031
Table 38. Asia-Pacific Long-Acting HIV-1 Inhibitors Market Size by Region (2020-2025) & (US$ Million)
Table 39. Asia-Pacific Long-Acting HIV-1 Inhibitors Market Size by Region (2026-2031) & (US$ Million)
Table 40. Latin America Long-Acting HIV-1 Inhibitors Market Size Growth Rate by Country (US$ Million): 2020 VS 2024 VS 2031
Table 41. Latin America Long-Acting HIV-1 Inhibitors Market Size by Country (2020-2025) & (US$ Million)
Table 42. Latin America Long-Acting HIV-1 Inhibitors Market Size by Country (2026-2031) & (US$ Million)
Table 43. Middle East & Africa Long-Acting HIV-1 Inhibitors Market Size Growth Rate by Country (US$ Million): 2020 VS 2024 VS 2031
Table 44. Middle East & Africa Long-Acting HIV-1 Inhibitors Market Size by Country (2020-2025) & (US$ Million)
Table 45. Middle East & Africa Long-Acting HIV-1 Inhibitors Market Size by Country (2026-2031) & (US$ Million)
Table 46. GSK Company Details
Table 47. GSK Business Overview
Table 48. GSK Long-Acting HIV-1 Inhibitors Product
Table 49. GSK Revenue in Long-Acting HIV-1 Inhibitors Business (2020-2025) & (US$ Million)
Table 50. GSK Recent Development
Table 51. Frontier Biotechnologies Company Details
Table 52. Frontier Biotechnologies Business Overview
Table 53. Frontier Biotechnologies Long-Acting HIV-1 Inhibitors Product
Table 54. Frontier Biotechnologies Revenue in Long-Acting HIV-1 Inhibitors Business (2020-2025) & (US$ Million)
Table 55. Frontier Biotechnologies Recent Development
Table 56. Gilead Sciences Company Details
Table 57. Gilead Sciences Business Overview
Table 58. Gilead Sciences Long-Acting HIV-1 Inhibitors Product
Table 59. Gilead Sciences Revenue in Long-Acting HIV-1 Inhibitors Business (2020-2025) & (US$ Million)
Table 60. Gilead Sciences Recent Development
Table 61. ViiV Healthcare Company Details
Table 62. ViiV Healthcare Business Overview
Table 63. ViiV Healthcare Long-Acting HIV-1 Inhibitors Product
Table 64. ViiV Healthcare Revenue in Long-Acting HIV-1 Inhibitors Business (2020-2025) & (US$ Million)
Table 65. ViiV Healthcare Recent Development
Table 66. Johnson & Johnson Company Details
Table 67. Johnson & Johnson Business Overview
Table 68. Johnson & Johnson Long-Acting HIV-1 Inhibitors Product
Table 69. Johnson & Johnson Revenue in Long-Acting HIV-1 Inhibitors Business (2020-2025) & (US$ Million)
Table 70. Johnson & Johnson Recent Development
Table 71. MSD Company Details
Table 72. MSD Business Overview
Table 73. MSD Long-Acting HIV-1 Inhibitors Product
Table 74. MSD Revenue in Long-Acting HIV-1 Inhibitors Business (2020-2025) & (US$ Million)
Table 75. MSD Recent Development
Table 76. Research Programs/Design for This Report
Table 77. Key Data Information from Secondary Sources
Table 78. Key Data Information from Primary Sources
Table 79. Authors List of This Report
List of Figures
Figure 1. Long-Acting HIV-1 Inhibitors Picture
Figure 2. Global Long-Acting HIV-1 Inhibitors Market Size Comparison by Type (2020-2031) & (US$ Million)
Figure 3. Global Long-Acting HIV-1 Inhibitors Market Share by Type: 2024 VS 2031
Figure 4. Long-Acting Injection Features
Figure 5. Long-Acting Oral Features
Figure 6. Global Long-Acting HIV-1 Inhibitors Market Size by Application (2020-2031) & (US$ Million)
Figure 7. Global Long-Acting HIV-1 Inhibitors Market Share by Application: 2024 VS 2031
Figure 8. Hospital Case Studies
Figure 9. Clinic Case Studies
Figure 10. Others Case Studies
Figure 11. Long-Acting HIV-1 Inhibitors Report Years Considered
Figure 12. Global Long-Acting HIV-1 Inhibitors Market Size (US$ Million), Year-over-Year: 2020-2031
Figure 13. Global Long-Acting HIV-1 Inhibitors Market Size, (US$ Million), 2020 VS 2024 VS 2031
Figure 14. Global Long-Acting HIV-1 Inhibitors Market Share by Region: 2024 VS 2031
Figure 15. Global Long-Acting HIV-1 Inhibitors Market Share by Players in 2024
Figure 16. Global Long-Acting HIV-1 Inhibitors Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
Figure 17. The Top 10 and 5 Players Market Share by Long-Acting HIV-1 Inhibitors Revenue in 2024
Figure 18. North America Long-Acting HIV-1 Inhibitors Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 19. North America Long-Acting HIV-1 Inhibitors Market Share by Country (2020-2031)
Figure 20. United States Long-Acting HIV-1 Inhibitors Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 21. Canada Long-Acting HIV-1 Inhibitors Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 22. Europe Long-Acting HIV-1 Inhibitors Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 23. Europe Long-Acting HIV-1 Inhibitors Market Share by Country (2020-2031)
Figure 24. Germany Long-Acting HIV-1 Inhibitors Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 25. France Long-Acting HIV-1 Inhibitors Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 26. U.K. Long-Acting HIV-1 Inhibitors Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 27. Italy Long-Acting HIV-1 Inhibitors Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 28. Russia Long-Acting HIV-1 Inhibitors Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 29. Ireland Long-Acting HIV-1 Inhibitors Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 30. Asia-Pacific Long-Acting HIV-1 Inhibitors Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 31. Asia-Pacific Long-Acting HIV-1 Inhibitors Market Share by Region (2020-2031)
Figure 32. China Long-Acting HIV-1 Inhibitors Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 33. Japan Long-Acting HIV-1 Inhibitors Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 34. South Korea Long-Acting HIV-1 Inhibitors Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 35. Southeast Asia Long-Acting HIV-1 Inhibitors Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 36. India Long-Acting HIV-1 Inhibitors Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 37. Australia & New Zealand Long-Acting HIV-1 Inhibitors Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 38. Latin America Long-Acting HIV-1 Inhibitors Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 39. Latin America Long-Acting HIV-1 Inhibitors Market Share by Country (2020-2031)
Figure 40. Mexico Long-Acting HIV-1 Inhibitors Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 41. Brazil Long-Acting HIV-1 Inhibitors Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 42. Middle East & Africa Long-Acting HIV-1 Inhibitors Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 43. Middle East & Africa Long-Acting HIV-1 Inhibitors Market Share by Country (2020-2031)
Figure 44. Israel Long-Acting HIV-1 Inhibitors Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 45. Saudi Arabia Long-Acting HIV-1 Inhibitors Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 46. UAE Long-Acting HIV-1 Inhibitors Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 47. GSK Revenue Growth Rate in Long-Acting HIV-1 Inhibitors Business (2020-2025)
Figure 48. Frontier Biotechnologies Revenue Growth Rate in Long-Acting HIV-1 Inhibitors Business (2020-2025)
Figure 49. Gilead Sciences Revenue Growth Rate in Long-Acting HIV-1 Inhibitors Business (2020-2025)
Figure 50. ViiV Healthcare Revenue Growth Rate in Long-Acting HIV-1 Inhibitors Business (2020-2025)
Figure 51. Johnson & Johnson Revenue Growth Rate in Long-Acting HIV-1 Inhibitors Business (2020-2025)
Figure 52. MSD Revenue Growth Rate in Long-Acting HIV-1 Inhibitors Business (2020-2025)
Figure 53. Bottom-up and Top-down Approaches for This Report
Figure 54. Data Triangulation
Figure 55. Key Executives Interviewed
